395 related articles for article (PubMed ID: 32047535)
21. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
22. Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.
Kian W; Krayim B; Alsana H; Giles B; Purim O; Alguayn W; Alguayn F; Peled N; Roisman LC
Front Oncol; 2023; 13():1124949. PubMed ID: 36923435
[TBL] [Abstract][Full Text] [Related]
23. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
24. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
25. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.
Chou YT; Lin CC; Lee CT; Pavlick DC; Su PL
Front Oncol; 2022; 12():838798. PubMed ID: 35372088
[No Abstract] [Full Text] [Related]
26. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
28. [Cancer Therapy Targeting Fusion Genes in Lung Cancer].
Tateishi A; Goto Y
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1043-1047. PubMed ID: 36281592
[TBL] [Abstract][Full Text] [Related]
29. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
30. [Research Progress of Targeted Therapy for BRAF Mutation
in Advanced Non-small Cell Lung Cancer].
Liu X; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):635-640. PubMed ID: 30172272
[TBL] [Abstract][Full Text] [Related]
31. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N
Front Oncol; 2023; 13():1275575. PubMed ID: 38023198
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
Front Oncol; 2016; 6():112. PubMed ID: 27200298
[TBL] [Abstract][Full Text] [Related]
33. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
35. Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.
Chan KI; Vong HT; Sin LF; Yip YC; Zhong XY; Wen JM
Clin Respir J; 2018 Apr; 12(4):1416-1423. PubMed ID: 28756651
[TBL] [Abstract][Full Text] [Related]
36. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
Khoo C; Rogers TM; Fellowes A; Bell A; Fox S
Transl Lung Cancer Res; 2015 Apr; 4(2):126-41. PubMed ID: 25870795
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
38. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
39. Genetic predictors of MEK dependence in non-small cell lung cancer.
Pratilas CA; Hanrahan AJ; Halilovic E; Persaud Y; Soh J; Chitale D; Shigematsu H; Yamamoto H; Sawai A; Janakiraman M; Taylor BS; Pao W; Toyooka S; Ladanyi M; Gazdar A; Rosen N; Solit DB
Cancer Res; 2008 Nov; 68(22):9375-83. PubMed ID: 19010912
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.
Rittberg R; Banerji S; Green S; Qing G; Dawe DE
Cureus; 2020 Oct; 12(10):e11224. PubMed ID: 33269152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]